Statistically significant lower risk is seen for mortality, hospitalization, progression, recovery, and cases. 14 studies from 14 independent teams in 8 countries show statistically significant improvements.
Meta analysis using the most serious outcome reported shows 39% [22‑53%] lower risk. Results are similar for Randomized Controlled Trials.
Results are robust — in exclusion sensitivity analysis 12 of 21 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective.
All data to reproduce this paper and sources are in the appendix. Other meta analyses show significant improvements with fluvoxamine for mortality Deng, hospitalization Deng, Deng (B), Lee, Lu, Marcec, and severity Nakhaee.
Covid Analysis et al., Mar 2024, preprint, 1 author.